← Back to Search

MRI for Pediatric Astrocytoma

Phase 2
Waitlist Available
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of low grade astrocytoma in the hypothalamus, brain stem, or thalamus of 5 cm on T2 weighted scans
Previously treated with evidence of tumor progression
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if magnetic resonance imaging can help improve the ability to determine the growth rate of progressive astrocytoma in children.

Who is the study for?
This trial is for children aged 12 or under with a type of brain tumor called low-grade astrocytoma located in specific areas of the brain. They should have had an incomplete surgery to remove the tumor and show signs that the tumor is growing again. The size of the tumor must be noticeable on certain MRI scans.
What is being tested?
The study is testing how effective magnetic resonance imaging (MRI) is in monitoring the growth rate of progressive low-grade astrocytomas in children. It's a Phase II trial, which means it's checking if this imaging method works well and provides accurate information about these tumors.
What are the potential side effects?
Since this trial focuses on using MRI for imaging rather than treatment, there are no direct side effects from medications or interventions typically associated with clinical trials. However, some kids might find lying still inside an MRI machine uncomfortable.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My brain tumor is a low grade astrocytoma in a specific area and is 5 cm in size on scans.
Select...
My cancer has grown despite previous treatments.
Select...
My surgery did not remove all of my cancer.
Select...
I am 12 years old or younger.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
370 Previous Clinical Trials
35,170 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,928 Previous Clinical Trials
41,018,115 Total Patients Enrolled
Jeffry Alger, PhDStudy ChairJonsson Comprehensive Cancer Center
2 Previous Clinical Trials
1 Total Patients Enrolled

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00005084 — Phase 2
Brain Tumor Research Study Groups:
Brain Tumor Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00005084 — Phase 2
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005084 — Phase 2
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top